Key facts
- It has raised $15.5M; the latest was Early Stage VC ($13.9M) in Aug 2025.
- Notable investors include GL Ventures, IDG Capital, YuanBio Venture Capital, Goldport Capital, Shenzhen Angel Investment Guiding Fund — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for MagicRNA
- ·The full record, as it builds
Funding rounds
No funding rounds for MagicRNA are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MagicRNA
Developer and researcher of RNA drugs designed to treat cancer. The company focuses on the development of an ionizable amino lipid library, and engages in the development and production of nucleic acid drug delivery and RNA drugs, enabling medical industry clients to provide them with related pharmaceutical products and services.
- Sector
- Healthcare
- HQ
- Shenzhen, China
- Founded
- 2021
- Website
- magicrna.com/
- Ownership
- Privately Held (backing)
MagicRNA doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MagicRNA shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MagicRNA in its N-PORT filings yet. We sweep new filings monthly.